About ABBISKO-B Company

We are an R&D-driven clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. Since inception, we have built a strong internal R&D engine, supported by our outstanding discovery team and multi-dimensional discovery platform. With strong discovery capabilities, we have strategically designed and developed more than 10 oncology-focused projects, including five in the clinical phase. We aspire to be a leading biopharmaceutical company to discover and develop novel differentiated therapies in cancer and other fields to meet the critical unmet needs of patients in China and around the world. We strategically focus on small molecule precision oncology therapy, small molecule immuno-oncology, and combination therapies. With their good efficacy and safety, we believe this is the development trend and next generation solution for cancer treatment.